Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219497 | 0.87 | CA2 (0.48) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL15219465 | 0.87 | CA2 (0.48) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL8228745 | 0.86 | CA2 (0.52) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL6954907 | 0.83 | CYP4F2 (0.48) | CYP4F2CYP4A11 | |
| SCHEMBL10635985 | 0.83 | DRD2 (0.56) | — | |
| SCHEMBL7981034 | 0.82 | CYP4F2 (0.47) | CA2L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL6307386 | 0.82 | CYP4F2 (0.47) | CA2L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL6745996 | 0.82 | CYP4F2 (0.47) | CA2L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL5640207 | 0.82 | CYP4F2 (0.47) | KCNH2GRIN2BL3MBTL1GLACYP4F2 | |
| Toluene SCHEMBL6346328 | 0.81 | CYP4F2 (0.43) | SIGMAR1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903227-B2 | Synthesis of 2-acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2001092250-A2 | SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001087871-A2 | METHODS FOR PRODUCING AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| US-5925662-A | OXIDASE INHIBITORS | SYNTHELABO (FR) | 1999-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | PLA2G7, PAFAH1B2, PAFAH1B3 | CA2 147/4885SIGMAR1 4662/4885HTR1A 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.